BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 35077347)

  • 1. [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
    Santos MJ
    Acta Med Port; 2022 Mar; 35(3):209-215. PubMed ID: 35077347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
    Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
    Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid disorders induced by checkpoint inhibitors.
    Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
    Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
    JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How we treat endocrine complications of immune checkpoint inhibitors.
    Paschou SA; Stefanaki K; Psaltopoulou T; Liontos M; Koutsoukos K; Zagouri F; Lambrinoudaki I; Dimopoulos MA
    ESMO Open; 2021 Feb; 6(1):100011. PubMed ID: 33399077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
    Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
    J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor-related hypophysitis.
    Mizukoshi T; Fukuoka H; Takahashi Y
    Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101668. PubMed ID: 35562229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
    Bai X; Lin X; Zheng K; Chen X; Wu X; Huang Y; Zhuang Y
    Endocrine; 2020 Sep; 69(3):670-681. PubMed ID: 32507965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
    Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
    Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Endocrinopathies induced by immune checkpoint inhibitors].
    Jaafar J; Mavromati M; Philippe J
    Rev Med Suisse; 2018 Jan; 14(588-589):34-38. PubMed ID: 29337446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors and endocrine side effects, a narrative review.
    Agrawal L; Bacal A; Jain S; Singh V; Emanuele N; Emanuele M; Meah F
    Postgrad Med; 2020 Mar; 132(2):206-214. PubMed ID: 31876444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The side effects of immune checkpoint inhibitor therapy on the endocrine system.
    Goyal I; Pandey MR; Sharma R; Chaudhuri A; Dandona P
    Indian J Med Res; 2021 Apr; 154(4):559-570. PubMed ID: 35435341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces.
    Deligiorgi MV; Liapi C; Trafalis DT
    Expert Opin Biol Ther; 2021 Aug; 21(8):1097-1120. PubMed ID: 33393372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine toxicities of immune checkpoint inhibitors.
    Wright JJ; Powers AC; Johnson DB
    Nat Rev Endocrinol; 2021 Jul; 17(7):389-399. PubMed ID: 33875857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
    Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y
    Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine immune-related adverse effects of immune-checkpoint inhibitors.
    Trevisani V; Iughetti L; Lucaccioni L; Predieri B
    Expert Rev Endocrinol Metab; 2023; 18(5):441-451. PubMed ID: 37682107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment.
    Di Dalmazi G; Ippolito S; Lupi I; Caturegli P
    Expert Rev Endocrinol Metab; 2019 Nov; 14(6):381-398. PubMed ID: 31842671
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.